Recent News

• 05.28.2026 - CG Oncology to Present at Upcoming Investor Conferences in June
• 05.19.2026 - SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• 05.15.2026 - AUA 2026 – CORE 008 Cohort CX Presentation
• 05.15.2026 - CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• 05.11.2026 - CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
• 05.08.2026 - CG Oncology Reports…
• 05.05.2026 - CG Oncology to Present…

Recent Filings

• 05.26.2026 - 8-K Current report
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.08.2026 - EX-99.1 EX-99.1
• 05.08.2026 - 8-K Current report
• 05.08.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.24.2026 - DEF 14A Other definitive proxy statements
• 04.24.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.24.2026 - ARS Annual Report to Security Holders
• 04.20.2026 - 4 Statement of changes in beneficial ownership of securities